US 6,982,081 B2
Composition for treatment of and method of monitoring hepatitis C virus using interferon-TAU
Yoshihiro Sokawa, Kyoto (Japan); and Chih-Ping Liu, San Francisco, Calif. (US)
Assigned to Pepgen Corporation, Alameda, Calif. (US)
Filed on Jul. 19, 2001, as Appl. No. 9/910,406.
Claims priority of provisional application 60/219128, filed on Jul. 19, 2000.
Prior Publication US 2003/0049277 A1, Mar. 13, 2003
Int. Cl. A61K 38/21 (2006.01)
U.S. Cl. 424—85.4 9 Claims
 
1. A method for decreasing the alanine aminotransferase (ALT) blood level in a human subject infected with hepatitis C virus (HCV), comprising
orally administering interferon-tau to the subject at a daily dosage between 2×108-1010 Units, said dosage effective to decrease bloodstream levels of ALT relative to bloodstream levels of ALT prior to treatment.